Crossmark

A Novel Spectrofluorimetric Method for Vibegron in the Newly FDA Approved Pharmaceutical Formulation and in Human Plasma: Analytical QbD Strategy for Method Development and Optimization

Crossref DOI link: https://doi.org/10.1007/s10895-024-04020-0

Published Online: 2024-11-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wadie, Mina https://orcid.org/0000-0001-7467-7469
Tantawy, Mahmoud A.

Goda, Zeinab M.
Funding

Funding for this research was provided by:

Cairo University
License Information

Text and Data Mining valid from 2024-11-16

Version of Record valid from 2024-11-16
More Information

Article History

Received: 31 August 2024

Accepted: 29 October 2024

First Online: 16 November 2024

Declarations

:

: There are no human subjects in this research and informed consent is not applicable.

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below